AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30290902 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at 1.8 mg/kg via intravenous infusion once every 3 weeks for up to 16 cycles (recommended phase 2 dose).
Number of subjects: 36
Study 30290902 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at 1.8 mg/kg.
Number of subjects: 36
Study 26192078 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support interventions for care staff
Number of subjects: 119
Study 25209438 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 0
Study 25209438 — intervention group
Group type: COMPARATOR
Intervention: Vertical banded gastroplasty
Number of subjects: 0
Study 22220931 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (300 mg, t.i.d., for 30 days)
Number of subjects: 130
Study 22220931 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 130
Study 22220931 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 130
Study 21070197 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin protection cushion (SPC)
Number of subjects: 232
Study 21070197 — intervention group
Group type: COMPARATOR
Intervention: Segmented foam cushion (SFC)
Number of subjects: 232
Study 17112401 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+OT (treatment as usual plus occupational therapy)
Number of subjects: 62
Study 17112401 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 62
Study 16148823 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (0.1 mg/kg)
Number of subjects: 0
Study 16148823 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose epinephrine
Number of subjects: 0
Study 11949897 — intervention group
Group type: EXPERIMENTAL
Intervention: Early training (ET) - 16 weeks of training involving drawing common objects and highlighting the relation between pictures and their referents.
Number of subjects: 16
Study 11949897 — intervention group
Group type: COMPARATOR
Intervention: Late training (LT) - Placebo version of training for 16 weeks followed by actual training for 4 weeks in the fifth month.
Number of subjects: 16
Study 10983527 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg single dose
Number of subjects: 134
Study 10983527 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg two doses on 2 consecutive days
Number of subjects: 134
Study 7483385 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapy
Number of subjects: 0
Study 7483385 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 1976576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine treatment for four weeks
Number of subjects: 9
Study 1976576 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid treatment for four weeks
Number of subjects: 9
Study 1976576 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment after sulphasalazine
Number of subjects: 9
Study 7241460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure therapy
Number of subjects: 0
Study 30392872 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-enhanced nebulizer
Number of subjects: 107
Study 30392872 — intervention group
Group type: COMPARATOR
Intervention: Conventional jet nebulizer
Number of subjects: 107
Study 30392872 — intervention group
Group type: COMPARATOR
Intervention: Conventional jet nebulizer (subgroup analysis)
Number of subjects: 107
Study 30392872 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-enhanced nebulizer (subgroup analysis)
Number of subjects: 107
Study 28669278 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin for 7 days in the study group (n = 165)
Number of subjects: 315
Study 28669278 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo, n = 150)
Number of subjects: 315
Study 25917659 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 0
Study 23333663 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.05 mg/kg/d
Number of subjects: 52
Study 23333663 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.10 mg/kg/d
Number of subjects: 52
Study 23333663 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 52
Study 23333663 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide (both doses)
Number of subjects: 52
Study 21407126 — intervention group
Group type: EXPERIMENTAL
Intervention: MD + fructose (2:1)
Number of subjects: 10
Study 21407126 — intervention group
Group type: EXPERIMENTAL
Intervention: MD + galactose (2:1)
Number of subjects: 10
Study 21407126 — intervention group
Group type: COMPARATOR
Intervention: MD + glucose (2:1)
Number of subjects: 10
Study 19192472 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 1068
Study 19192472 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1068
Study 19192472 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 1068
Study 17365203 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized asthma education session (group 1)
Number of subjects: 212
Study 17365203 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced asthma education (group 2)
Number of subjects: 212
Study 17365203 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced asthma education plus case management (group 3)
Number of subjects: 212
Study 15586183 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educative group-based treatment programme (8 weeks, weekly sessions of 2.5 hours, booster sessions after 1, 2, and 4 months)
Number of subjects: 155
Study 15586183 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 155
Study 16283926 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright green light (1,200 Lux)
Number of subjects: 33
Study 16283926 — intervention group
Group type: COMPARATOR
Intervention: Dim red light placebo (<10 Lux)
Number of subjects: 33
Study 10353380 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV seropositive participants on Stroop task
Number of subjects: 72
Study 10353380 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-and-pencil version of the Stroop task
Number of subjects: 72
Study 10353380 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop-RT version of the Stroop task
Number of subjects: 72
Study 10353380 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking manipulation on Stroop-RT
Number of subjects: 72
Study 10353380 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 72
Study 8595765 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 388
Study 8595765 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 388
Study 1849159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 1849159 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral ACV (started 7 days before or 5 min after UVR)
Number of subjects: 196
Study 1849159 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral ACV (started 48 h after UVR)
Number of subjects: 196
Study 1849159 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ACV (started 5 min after UVR)
Number of subjects: 196
Study 6277698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic estrogen regimen (0.625 mg of conjugated estrogens, 3 weeks on, 1 week off)
Number of subjects: 25
Study 6277698 — intervention group
Group type: COMPARATOR
Intervention: Continuous estrogen regimen (0.625 mg of conjugated estrogens, daily)
Number of subjects: 25
Study 29509315 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean-seafood diet
Number of subjects: 20
Study 29509315 — intervention group
Group type: COMPARATOR
Intervention: Non-seafood diet
Number of subjects: 20
Study 29509315 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 20
Study 28705181 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 0
Study 26682998 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 and omega-6 supplements for 12 weeks
Number of subjects: 76
Study 26682998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 23860544 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching emotional intelligence
Number of subjects: 52
Study 23860544 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 21182509 — intervention group
Group type: EXPERIMENTAL
Intervention: FSL phototherapy (twice per week for 4 weeks)
Number of subjects: 38
Study 21182509 — intervention group
Group type: EXPERIMENTAL
Intervention: FSL phototherapy
Number of subjects: 38
Study 21182509 — intervention group
Group type: COMPARATOR
Intervention: Control (emollient application only)
Number of subjects: 38
Study 19947442 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrofoon
Number of subjects: 50
Study 19947442 — intervention group
Group type: COMPARATOR
Intervention: Sublingual nimesulide
Number of subjects: 50
Study 17511722 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-based screening
Number of subjects: 3758
Study 17511722 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA < 4 ng/mL with doubtful DRE finding
Number of subjects: 3758
Study 17511722 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional systematic sextant biopsies
Number of subjects: 3758
Study 15322648 — intervention group
Group type: EXPERIMENTAL
Intervention: RS system packing method
Number of subjects: 40
Study 15322648 — intervention group
Group type: COMPARATOR
Intervention: Conventional packing method
Number of subjects: 40
Study 11437873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (10 mL h(‐1))
Number of subjects: 109
Study 11437873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (10 mL h(‐1))
Number of subjects: 109
Study 11437873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 0.5 microg mL(‐1) sufentanil (BS)
Number of subjects: 109
Study 11437873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine with 0.5 microg mL(‐1) sufentanil (RS)
Number of subjects: 109
Study 11437873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg mL(‐1) sufentanil only (S)
Number of subjects: 109
Study 11437873 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine plus sufentanil
Number of subjects: 109
Study 9881243 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 37
Study 9881243 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea treatment
Number of subjects: 37
Study 8275737 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted breathing retraining (BRT) with pneumographic or strain-gauge feedback and electromyogram feedback, 8 sessions.
Number of subjects: 26
Study 8275737 — intervention group
Group type: COMPARATOR
Intervention: Control group received biofeedback-assisted (hand warming) relaxation training.
Number of subjects: 26
Study 8275737 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted breathing retraining (BRT)
Number of subjects: 26
Study 31395416 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher birth weight (third quintile)
Number of subjects: 1669
Study 31395416 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher birth weight (fourth quintile)
Number of subjects: 1669
Study 31395416 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher birth weight (top quintile)
Number of subjects: 1669
Study 31395416 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight in higher three quintiles
Number of subjects: 1669
Study 31395416 — intervention group
Group type: COMPARATOR
Intervention: Reference group (second quintile of birth weight)
Number of subjects: 1669
Study 28943321 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP group (M1)
Number of subjects: 181
Study 28943321 — intervention group
Group type: EXPERIMENTAL
Intervention: O2 flow group (M2)
Number of subjects: 181
Study 28943321 — intervention group
Group type: EXPERIMENTAL
Intervention: Air flow group (M3)
Number of subjects: 181
Study 27029390 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for chronic progressive diseases (specific intervention details not available)
Number of subjects: 0
Study 25545540 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (100 μg/kg per min for 10 mins, then 50 μg/kg per min for 50 mins)
Number of subjects: 14
Study 25545540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecadenoson (75 μg)
Number of subjects: 14
Study 25545540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecadenoson (300 μg)
Number of subjects: 14
Study 22562973 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate (ADA+MTX)
Number of subjects: 1032
Study 22562973 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy (PBO+MTX)
Number of subjects: 1032
Study 22219096 — intervention group
Group type: EXPERIMENTAL
Intervention: BMSC transplantation
Number of subjects: 60
Study 22219096 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 60
Study 18446847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE)
Number of subjects: 80
Study 16946216 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice fortified with calcium
Number of subjects: 72
Study 16946216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy
Number of subjects: 72
Study 16946216 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study 12971145 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 2 embryo transfer
Number of subjects: 106
Study 12971145 — intervention group
Group type: COMPARATOR
Intervention: Day 3 embryo transfer
Number of subjects: 106
Study 10601674 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear, induced by exposure to three brief shocks
Number of subjects: 60
Study 10601674 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety, elicited by the threat of shock
Number of subjects: 60
Study 10601674 — intervention group
Group type: COMPARATOR
Intervention: Neutral, with no intervention
Number of subjects: 60
Study 9135961 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans monounsaturated fatty acid (TMUFA) diet
Number of subjects: 16
Study 9135961 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fat (SAT) diet
Number of subjects: 16
Study 9135961 — intervention group
Group type: COMPARATOR
Intervention: Cis monounsaturated fatty acid (CMUFA) diet
Number of subjects: 16
Study 8212369 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 52
Study 8212369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 3096035 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (T)
Number of subjects: 15
Study 3096035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3096035 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (T) infusion
Number of subjects: 15
Study 3096035 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study 3096035 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (T) with propranolol
Number of subjects: 15
Study 3096035 — intervention group
Group type: COMPARATOR
Intervention: Saline with propranolol
Number of subjects: 15
Study 3096035 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (T) and Saline
Number of subjects: 15
Study 29898844 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4600
Study 29898844 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 4600
Study 29898844 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4600
Study 29898844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4600
Study 26586786 — intervention group
Group type: EXPERIMENTAL
Intervention: MTP-131 infused at a rate of 0.05 mg/kg/h for 1 h
Number of subjects: 0
Study 26586786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26586786 — intervention group
Group type: EXPERIMENTAL
Intervention: MTP-131
Number of subjects: 0
Study 24145543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir at 5 mg/kg body weight intravenously
Number of subjects: 9
Study 24145543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir dose of 2.5 mg/kg once daily
Number of subjects: 9
Study 22001666 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (at least 2 daily sessions of music listening between D0 and D10, continued at home until D60)
Number of subjects: 87
Study 22001666 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only (control group)
Number of subjects: 87
Study 22001666 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 87
Study 19846597 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hemiagenesis (THA)
Number of subjects: 40
Study 19846597 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects with fully developed thyroid gland)
Number of subjects: 40
Study 18763685 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (2.5% lidocaine/2.5% prilocaine)
Number of subjects: 40
Study 18763685 — intervention group
Group type: COMPARATOR
Intervention: Oraqix thermosetting gel (2.5% lidocaine/2.5% prilocaine)
Number of subjects: 40
Study 16053244 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein source tryptophan (deoiled gourd seed) with carbohydrate
Number of subjects: 57
Study 16053244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical grade tryptophan with carbohydrate
Number of subjects: 57
Study 16053244 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate alone
Number of subjects: 57
Study 16053244 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein source tryptophan with carbohydrate
Number of subjects: 57
Study 14748645 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency words
Number of subjects: 8
Study 14748645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency words
Number of subjects: 8
Study 14748645 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density words
Number of subjects: 8
Study 14748645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density words
Number of subjects: 8
Study 9915370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis set at neutral with a flat sole line
Number of subjects: 1
Study 9915370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis
Number of subjects: 1
Study 9915370 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing-up motion restoration
Number of subjects: 1
Study 8534467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellation of elective surgery due to URI
Number of subjects: 212
Study 8534467 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of anesthesiologists
Number of subjects: 212
Study 8534467 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing cancellation decisions
Number of subjects: 212
Study 2139413 — intervention group
Group type: EXPERIMENTAL
Intervention: synthetic ANF‐(99‐126) 50 micrograms bolus followed by 0.025 micrograms.kg‐1.min‐1
Number of subjects: 10
Study 2139413 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium nitroprusside (SNP) 0.35 micrograms.kg‐1. min‐1
Number of subjects: 10
Study 2139413 — intervention group
Group type: COMPARATOR
Intervention: vehicle 0.9% NaCl40 ml and 20% albumin 5 ml
Number of subjects: 10
Study 6992833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 10-9359 (100 mg daily initially, maintenance dose 50 mg)
Number of subjects: 97
Study 6992833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 30872600 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography Texture Analysis (CTTA) combined with heterogeneity and radiomic features
Number of subjects: 253
Study 27681710 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental training groups for early specialisation path
Number of subjects: 76
Study 27681710 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental training groups for late specialisation path
Number of subjects: 76
Study 27681710 — intervention group
Group type: COMPARATOR
Intervention: Non-structured path
Number of subjects: 76
Study 27260011 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized lifestyle advice plus tandem skydive
Number of subjects: 132
Study 27260011 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized lifestyle advice only
Number of subjects: 132
Study 27260011 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 132
Study 27260011 — intervention group
Group type: COMPARATOR
Intervention: Non-anhedonic control group
Number of subjects: 132
Study 24806030 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose/metformin 50/500 mg FDC (test)
Number of subjects: 40
Study 24806030 — intervention group
Group type: COMPARATOR
Intervention: Acarbose 50 mg and metformin 500 mg as loose combination (reference)
Number of subjects: 40
Study 24806030 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg
Number of subjects: 40
Study 24806030 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg
Number of subjects: 40
Study 24806030 — intervention group
Group type: COMPARATOR
Intervention: Acarbose/metformin FDC and loose combination
Number of subjects: 40
Study 22504653 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 0
Study 19513933 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate level of transference interpretations
Number of subjects: 100
Study 19513933 — intervention group
Group type: COMPARATOR
Intervention: No transference interpretations
Number of subjects: 100
Study 17205427 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 16344839 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS XR 20‐60 mg/day
Number of subjects: 223
Study 12170853 — intervention group
Group type: EXPERIMENTAL
Intervention: ITI implant system
Number of subjects: 72
Study 12170853 — intervention group
Group type: EXPERIMENTAL
Intervention: Steri-Oss implant system
Number of subjects: 72
Study 12170853 — intervention group
Group type: EXPERIMENTAL
Intervention: Southern implant system
Number of subjects: 72